Foundation Fighting Blindness
Foundation Fighting Blindness
Add to My Podcasts
Episodes
About
Reviews
Promote
ARVO 2025 Highlight: PYC Reports Encouraging Phase 1/2 Clinical Trial Results for its RNA Therapy Targeting RP (PRPF31 Mutations)
4 minutes
Posted May 13, 2025 at 4:53 pm.
0:00
4:53
Add to My Queue
Download
MP3
Share
episode
Share at current time
Show notes
The company is planning a Phase 2/3 clinical trial for therapy in late 2025.
Previous
ARVO 2025 Highlight: Atsena’s XLRS Gene Therapy Provides Vision and Structural Improvements in Phase 1/2 Clinical Trial
Next
J&J’s XLRP Gene Therapy Didn’t Meet Primary Endpoint in Phase 3 Clinical Trial
← See all 261 episodes of Foundation Fighting Blindness
